Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder
NCT ID: NCT01515215
Last Updated: 2016-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
107 participants
INTERVENTIONAL
2008-07-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Several reasons may account for this modest therapeutic effect. First, the majority of these studies involved left-sided treatment alone to the dorsolateral prefrontal cortex (DLPFC), which is a significant limitation when considering that electroconvulsive therapy - another form of brain stimulation used in TRD - has been shown to be less efficacious when used unilaterally, compared to bilaterally.
Second, sub-optimal methods were utilized to target the DLPFC (i.e., '5-cm anterior method'), limiting the treatment potential of what is inherently a targeted form of treatment. In this regard, recent data from the investigators suggests that treatment directly targeting the DLPFC provides enhanced therapeutic efficacy compared to the '5-cm anterior' method.
Third, treatment durations were typically short (i.e., 2-4 weeks). Fourth, stimulation intensity may have been insufficient by not taking into consideration coil-to-cortex distance, which is of particular importance when considering that this parameter may contribute significantly to rTMS-induced antidepressant response. Fifth, there has not been a study that has examined TRD across the lifespan in a way that addresses the differences between older and younger adults. Therefore, the investigators propose to conduct a study evaluating the efficacy of rTMS for TRD that directly addresses all 5 of these major limitations.
This study will compare bilateral rTMS to unilateral rTMS and will involve targeting the DLPFC using cortical co-registration techniques, as well as treatments of optimal duration (i.e., up to 6 weeks) and intensity parameters (i.e., adjusted for coil-to-cortex distance). The use of distance cortical co-registration and adjustment for coil-to-cortex distance addresses the major limitation (lack of stimulation intensity to compensate for age-related prefrontal atrophy) in studies that have examined rTMS in an elderly sample. Preliminary data from this research group provide compelling evidence that rTMS may, indeed, be effective when some of these limitations are optimized in both younger and older adults. Finally, it is also essential that research investigate the mechanisms of therapeutic efficacy, so that increases in understanding can be translated into enhanced treatment. For several reasons, cortical excitability may represent a neurophysiological process through which the therapeutic effects of rTMS are mediated. Recent advances in electroencephalography (EEG) technology now permit direct measurement of excitability from the DLPFC; thus, we are now able to ascertain whether these are mechanisms through which the therapeutic effects of rTMS in TRD are mediated.
Hypotheses:
Hypothesis 1: Treatment with bilateral and high frequency left rTMS (HFL-rTMS) will both result in a greater reduction in 17-item Hamilton Depression Rating Scale (HAM-D17) scores compared to sham rTMS.
Hypothesis 2: Bilateral rTMS will result in a significantly greater number of patients reaching criteria for therapeutic response and remission on the HAM-D17 compared to unilateral or sham rTMS.
Hypothesis 3: An increase of excitability following HFL-rTMS to the left DLPFC (in the case of bilateral rTMS or HFL-rTMS) and a decrease in excitability following low frequency right-rTMS (LFR-rTMS; in the case of bilateral rTMS) to the right DLPFC will mediate the relationship between rTMS and response in TRD. Finally, the induction of gamma activity following rTMS will be associated with improved treatment efficacy.
Hypothesis 4: rTMS will result in improved executive function in patients over age 60 with TRD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-frequency Left rTMS
Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.
Site of Stimulation: left hemisphere of DLPFC.
Frequency: 10 Hz.
Duration: 42 Trains, 5 second duration, 25 second inter-train interval.
Repetitive Transcranial Magnetic Stimulation
Magnetic pulses to specific brain regions. (MagPro X100)
Bilateral rTMS
Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.
Sites of Stimulation: right and left hemispheres of the DLPFC.
Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.
Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval.
Repetitive Transcranial Magnetic Stimulation
Magnetic pulses to specific brain regions. (MagPro X100)
Sham rTMS
Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
Repetitive Transcranial Magnetic Stimulation
Magnetic pulses to specific brain regions. (MagPro X100)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive Transcranial Magnetic Stimulation
Magnetic pulses to specific brain regions. (MagPro X100)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of MDD, as confirmed by the Structured Clinical Interview for the DSM-IV (SCID-IV)
* 18 - 85 years of age
* failed to achieve clinical response, or did not tolerate, at least 2 separate antidepressant trials of sufficient dosage for at least 6 wks
* have a score of 20 or greater on the HAM-D17
* have not had an increase or initiation of any psychoactive therapy in the 4 wks prior to testing
* if a woman of childbearing potential, must be on an effective means of birth control
Exclusion Criteria
* concomitant, major, unstable medical or neurologic illness
* history of seizures
* acutely suicidal and/or homicidal
* pregnant
* have metal implants
* history of psychosurgery
* co-morbid diagnosis of borderline and/or antisocial personality disorder. as confirmed by the SCID for Axis II Disorders (SCID-II)
* are currently (or in the past 4 weeks) taking more than 2 mg of lorazepam, or equivalent, daily
* ECT treatment in the current episode
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ontario Mental Health Foundation
OTHER_GOV
Centre for Addiction and Mental Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Z. J. Daskalakis
Chair, Temerty Centre for Therapeutic Brain Intervention
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Z. Jeffrey Daskalakis, MD, PhD.
Role: PRINCIPAL_INVESTIGATOR
Centre for Addiction and Mental Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hadas I, Sun Y, Lioumis P, Zomorrodi R, Jones B, Voineskos D, Downar J, Fitzgerald PB, Blumberger DM, Daskalakis ZJ. Association of Repetitive Transcranial Magnetic Stimulation Treatment With Subgenual Cingulate Hyperactivity in Patients With Major Depressive Disorder: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2019 Jun 5;2(6):e195578. doi: 10.1001/jamanetworkopen.2019.5578.
Trevizol AP, Goldberger KW, Mulsant BH, Rajji TK, Downar J, Daskalakis ZJ, Blumberger DM. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression. Int J Geriatr Psychiatry. 2019 Jun;34(6):822-827. doi: 10.1002/gps.5091. Epub 2019 Apr 8.
Voineskos D, Blumberger DM, Zomorrodi R, Rogasch NC, Farzan F, Foussias G, Rajji TK, Daskalakis ZJ. Altered Transcranial Magnetic Stimulation-Electroencephalographic Markers of Inhibition and Excitation in the Dorsolateral Prefrontal Cortex in Major Depressive Disorder. Biol Psychiatry. 2019 Mar 15;85(6):477-486. doi: 10.1016/j.biopsych.2018.09.032. Epub 2018 Oct 18.
Weissman CR, Blumberger DM, Brown PE, Isserles M, Rajji TK, Downar J, Mulsant BH, Fitzgerald PB, Daskalakis ZJ. Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression. J Clin Psychiatry. 2018 May/Jun;79(3):17m11692. doi: 10.4088/JCP.17m11692.
Related Links
Access external resources that provide additional context or updates about the study.
Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching hospital, fully affiliated with the University of Toronto, and a PAHO/WHO Collaborating Centre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
040 / 2008
Identifier Type: -
Identifier Source: org_study_id